Reductions in risk seen for all-cause, CV mortality and composite of atherosclerotic CV events.
The use of statins appears to benefit patients hospitalized with COVID-19, according to the findings of a retrospective study conducted in Hubei Province, China.
The FDA has accepted for review the supplemental New Drug Application (sNDA) for sacubitril/valsartan (Entresto; Novartis) in the treatment of heart failure with preserved ejection fraction.
Patients with small or greater amounts of myocardial injury had significantly increased risk for death.
Authors used umbrella review method to explore health outcomes associated with low-dose aspirin.
Adherence to antihypertensive treatment was associated with a reduced risk of death among elderly patients, including frail individuals, according to a large study published in Hypertension.
For patients with high coronary artery calcium score, mortality up with decreasing physical activity.
Patients with heart failure who remained on mineralocorticoid receptor antagonists after a hyperkalemia episode had a lower risk for major cardiovascular events than those who stopped taking the medications, a study found.
A study of 1029 living kidney donors in Norway found that they had significant 64% increased odds of ischemic heart disease compared with health controls.
In a study, cardiovascular structure and function at 5 years did not differ significantly among living kidney donors and healthy controls.